Patents Examined by Robert Schwartzman
  • Method for the immortalization of cells using conditionally transformed helper cells
    Patent number: 6174726
    Abstract: The invention is directed to a method for the preparation of a conditionally immortalized immortalization-helper cell (fuseme), the fusemes generated by said method, hybridoma cells prepared using said fusemes as well as a method for immortalization of mammalian cells using said fuseme cells. Further, the invention relates to the generation of T cells directed agaist tumor cells using a fuseme cell.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: January 16, 2001
    Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH
    Inventors: Martin Staege, Georg Bornkamm, Bettina Kempkes
  • Method for making full-length cDNA libraries
    Patent number: 6174669
    Abstract: Disclosed is a method for making full-length CDNA libraries, which is for making libraries of cDNAs having a length corresponding to a full-length of mRNAs and comprises the following steps of; binding a tag molecule to a diol structure present in 5′ Cap (7MeGpppN) sites of mRNAs, forming RNA-DNA hybrids by reverse transcription using primers such as oligo dT and the mRNAs connected with the tag molecule as templates, and separating RNA-DNA hybrids carrying a DNA corresponding to a full-length of mRNAs from the RNA-DNA hybrids formed above by using function of the tag molecule. To obtain mRNA connected with a tag molecule, the diol structure present in 5′ Cap site of mRNA is subjected to a ring-open reaction by oxidation with sodium periodate to form a dialdehyde and the dialdehyde is reacted with a tag molecule having a hydrazine terminus.
    Type: Grant
    Filed: November 20, 1996
    Date of Patent: January 16, 2001
    Assignee: The Institute of Physical and Chemical Research
    Inventors: Yoshihide Hayashizaki, Piero Carninci, Claudio Schneider
  • P53-regulated genes
    Patent number: 6171798
    Abstract: Many genes are identified as being p53-regulated which were not heretofore known to be p53-regulated. This includes both genes whose expression is induced and genes whose expression is repressed by the expression of wild-type p53. Monitoring expression of these genes is used to provide indications of p53 status in a cell. Such monitoring can also be used to screen for useful anti-cancer therapeutics, as well as for substances which are carcinogenic. Defects in p53 can be bypassed by supplying p53 induced genes to cells. Defects in p53 can also be bypassed by supplying antisense constructs to p53-repressed genes.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: January 9, 2001
    Assignees: Affymetrix, Inc., Princeton University
    Inventors: Arnold L. Levine, Maureen Elizabeth Murphy, David H. Mack, Kurt Carlyle Gish, Edward Yat Wah Tom
  • Heterologous polypeptides expressed in filamentous fungi, process for making same, and vectors for making same
    Patent number: 6171817
    Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: January 9, 2001
    Assignee: Genencor International, Inc.
    Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
  • Oligonucleotide tags for sorting and identification
    Patent number: 6172214
    Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention comprise oligonucleotides selected from a minimally cross-hybridizing set. Preferably, such oligonucleotides each consist of a plurality of subunits 3 to 9 nucleotides in length. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: January 9, 2001
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sydney Brenner
  • Antisense modulation of BCL-X expression
    Patent number: 6172216
    Abstract: Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: January 9, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Brett P. Monia, Brian J. Nickoloff, QingQing Zhang
  • Oligonucleotide tags for sorting and identification
    Patent number: 6172218
    Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention comprise oligonucleotides selected from a minimally cross-hybridizing set. Preferably, such oligonucleotides each consist of a plurality of subunits 3 to 9 nucleotides in length. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: January 9, 2001
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sydney Br{umlaut over (e)}nner
  • Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
    Patent number: 6171788
    Abstract: The nucleic acid upstream of the TIGR protein encoding sequence can be used to diagnose glaucoma. Polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to diagnose glaucoma. In addition, polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to prognose glaucoma.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: January 9, 2001
    Assignee: The Regents of the University of California
    Inventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen
  • NF-AT polypeptides and polynucleotides
    Patent number: 6171781
    Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: January 9, 2001
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
  • Genetic antiviral agents and methods for their use
    Patent number: 6168953
    Abstract: The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: January 2, 2001
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Boro Dropulic, Paula M. Pitha
  • Method of producing adenoviral vector stocks
    Patent number: 6168941
    Abstract: The present invention provides a method of producing an adenoviral vector stock by providing a culture of cells permissive for growth of adenoviral vectors, wherein the cells are in a medium, culturing the culture under conditions to permit growth of the cells, perfusing fresh medium through the culture for a period of about 1-6 hours, in an amount of at least about two times the volume of medium in the culture, while the density of the cells in the medium is about 40-70% of the density of cells obtained in the medium when the growth of the culture is in the stationary phase, contacting the culture with adenoviral vectors under conditions permissive for the infection of the cells after the perfusion of fresh medium is substantially completed, culturing the infected cells to replicate the adenoviral vectors, and harvesting the infected cells to obtain an adenoviral vector stock.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: January 2, 2001
    Assignee: GenVec, Inc.
    Inventors: Lee-Cheng Liu, Shoupeng Lai
  • Deoxynucleic alkyl thiourea compounds and uses thereof
    Patent number: 6169176
    Abstract: The invention provides novel deoxynucleic alkyl thiourea (dNXt) oligonucleotide compounds for use in antisense or antigene therapy.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: January 2, 2001
    Assignee: The Regents of the University of California
    Inventors: Thomas C. Bruice, Arya P. Dev
  • Antisense inhibition of E2F transcription factor 3 expression
    Patent number: 6165791
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Isolated nucleic acid molecule encoding human skeletal muscle-specific ubiquitin-conjugating enzyme
    Patent number: 6166190
    Abstract: An isolated nucleic acid molecule encoding human skeletal muscle-specific ubiquitin-conjugating enzyme and comprising a nucleotide sequence coding for the amino acid sequence shown in SEQ ID NO:22 is disclosed. The isolation of this molecule makes it possible to detect its expression in various tissues, analyze its structure and function, and produce the human proteins encoded by this molecule by the technology of genetic engineering. In this way, it is possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the molecule, for example hereditary diseases and cancer, and diagnose and treat such diseases.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: December 26, 2000
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tsutomu Fujiwara, Takeshi Watanabe
  • Antisense modulation of hnRNP A1 expression
    Patent number: 6165789
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hnRNP A1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hnRNP A1. Methods of using these compounds for modulation of hnRNP A1 expression and for treatment of diseases associated with expression of hnRNP A1 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Chromosome 21 gene marker, compositions and methods using same
    Patent number: 6166180
    Abstract: The present invention provides isolated nucleic acids encoding human EHOC-1 protein and isolated receptor proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing, antibodies that specifically bind to invention polypeptides and compositions containing, as well as transgenic non-human mammals that express the invention protein.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: December 26, 2000
    Assignee: Cedar-Sinai Medical Center
    Inventors: Julie R. Korenberg, Kazuhiro Yamakawa
  • Regulated transcription of targeted genes and other biological events
    Patent number: 6165787
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: December 26, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
  • Chemical modification of DNA using peptide nucleic acid conjugates
    Patent number: 6165720
    Abstract: Complexes comprising a nucleic acid molecule and a conjugated peptide nucleic acid (PNA). The PNA may be labeled or conjugated to a protein, peptide, carbohydrate moiety or receptor ligand. These complexes are used to transfect cells to monitoring plasmid biodistribution, promote nuclear localization, induce transcriptional activation, lyse the endosomal compartment and facilitate transfection. These complexes increase the efficiency of expression of a particular gene.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: December 26, 2000
    Assignees: Gene Therapy Systems, Isis Pharmaceuticals, Inc.
    Inventors: Philip L. Felgner, Olivier Zelphati, C. Frank Bennett
  • Antisense modulation of NCK-2 expression
    Patent number: 6165728
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of nck-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding nck-2. Methods of using these compounds for modulation of nck-2 expression and for treatment of diseases associated with expression of nck-2 are provided.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Method of expressing an exogenous nucleic acid
    Patent number: 6165754
    Abstract: The present invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises non-systemically administering to a non-neuronal tissue of said mammal an exogenous nucleic acid operatively linked to a promoter. The exogenous nucleic acid is proximal to at least one native parvoviral inverted terminal repeat and does not require encapsidation. The expression of the exogenous nucleic acid in the tissue is not substantially diminished at 28 days after administration of the exogenous nucleic acid.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: December 26, 2000
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Ronald G. Crystal, Xiaohuai Zhou, Neil R. Hackett, Todd K. Rosengart